Helicobacter pylori （Hp） infection is closely associated with inflammation，ulceration and malignancy in the upper gastrointestinal tract. However，with the progressive increase in resistance to commonly used antibiotics，the efficacy of existing eradication regimens has significantly decreased，and there is an urgent need to explore regimens with higher eradication rates. Vonoprazan is a novel potassium⁃competitive acid blockers （P ⁃CABs）with strong and long ⁃lasting acid ⁃ suppressive effects，and has shown good eradication effects against Hp，especially drug ⁃ resistant strains，in clinical practice. This article summarizes the current mechanism of action，efficacy，current status of research and safety of vonoprazan for Hp treatment，aiming to provide a reference for the promotion of vonoprazan for the treatment of Hp infection.